Phase I Study Of Intravenous DOTAP:Cholesterol-Fus1 Liposome Complex (DOTAP:Chol-fus1) In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy (Protocol #0201-513)

Table of Contents

Phase I Study Of Intravenous DOTAP:Cholesterol-Fus1 Liposome Complex (DOTAP:Chol-fus1) In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy (Protocol #0201-513)

Protocol #0201-513: Collaborators

GENE-BASED THERAPY

TIMING OF GENETIC CHANGES IN PRENEOPLASTIC LESIONS

PPT Slide

PPT Slide

EFFECTS OF 3p21.3 GENE EXPRESSION ON NSCLC CELLS AND NORMAL HUMAN BEC GROWTH

INDUCTION OF APOPTOSIS IN AD-3p21.3 GENE-TRANSDUCED CELLS

PPT Slide

PREDICTED SECONDARY STRUCTURE AND FUNCTIONAL DOMAINS OF FUS1 PROTEIN

MYRISTOYLATION OF FUS1 PROTEIN IN H1299 CELLS

IMMUNOHISTOCHEMICAL STAINING OF HUMAN NORMAL LUNG AND LUNG CANCER TISSUES WITH ANTI-Fus1 ANTIBODIES

STRUCTURE OF DOTAP-Chol-DNA COMPLEX

TREATMENT SCHEDULE OF LUNG METASTASIS

DISSEMINATION OF TUMORS TO VARIOUS ORGANS FROM CONTROL UNTREATED MICE INJECTED WITH H1299 TUMOR CELLS

DOTAP : Chol-p53 DNA:LIPOSOME TREATMENT REDUCES H1299 LUNG METASTASIS

EFFECT OF DOTAP:Chol-p53 DNA:LIPOSOME COMPLEX ON SURVIVAL OF H1299 LUNG TUMOR BEARING MICE

PPT Slide

PPT Slide

Protocol #0201-513: Preclinical Toxicity

Protocol #0201-513: Preclinical Toxicity, Autopsy Results

Protocol #0201-513: Preclinical Toxicity, Autopsy Results

Protocol #0201-513: Preclinical Toxicity, Summary

PPT Slide

PPT Slide

Protocol #0201-513: Background

Protocol #0201-513: Objectives

Protocol #0201-513: Treatment Plan

Protocol #0201-513: Evaluations during Study

Protocol #0201-513: Statistical Considerations

Protocol #0201-513: Study Design

mCRM (Theory)

mCRM (Application)

mCRM (Operating Characteristics)

Advantage of Using mCRM

Home Page: www.webconferences.com/nihoba